Hasil Pencarian (17430)
Halaman 170 / 349GRN163L is a novel anti-cancer drug. It has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many cancer types (including lung, breast, prostate, liver, and early stage of human breast cancer), in both cell culture syst…
Growth hormone-releasing peptide 1 is under investigation in clinical trial NCT00381602 (A Phase II, Randomized, Cross-over, Vehicle-controlled, Double-blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects…
Deskripsi belum tersedia.
GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence
GS-441524 is an adenosine nucleotide analog antiviral, similar to [remdesivir].[A203057,L13239] This molecule was patented in 2009.[L13775] _In vitro_ studies of GS-441524 have determined it has a higher EC<sub>50</sub> than remdesivir against a number of vir…
GS-5745 has been used in trials studying the treatment of Tumors, Breast Cancer, Crohn's Disease, Colorectal Cancer, and Pancreatic Cancer, among others.
GS-6620 is under investigation in clinical trial NCT01316237 (A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection).
GS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).
GS-9256 has been used in trials studying the treatment of HCV Infection and Chronic Hepatitis C Infection.
GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector. It is a com…
GSI-136 has been used in trials studying the treatment of Alzheimer Disease.
Gsk1004723 has been investigated for the treatment of Allergic Rhinitis and Rhinitis, Allergic, Seasonal.
GSK1059615 has been used in trials studying the treatment of Lymphoma, Solid Tumours, Endometrial Cancer, Solid Tumor Cancer, and Metastatic Breast Cancer.
GSK1292263 has been investigated for the treatment of DIABETES MELLITUS, TYPE 2.
GSK1521498 has been used in trials studying the treatment of Obesity and Alcoholism.
GSK2018682 has been investigated for the treatment of Multiple Sclerosis, Relapsing-Remitting.
GSK-239512 is under investigation in clinical trial NCT00474513 (An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.).
Gsk256066 has been used in trials studying the treatment and diagnostic of SAR, Asthma, Mild Asthma, Allergic Rhinitis, and Seasonal Allergic Rhinitis, among others.
GSK2636771 has been used in trials studying the treatment of CANCER, LYMPHOMA, Solid Neoplasm, Recurrent Solid Neoplasm, and Advanced Malignant Neoplasm, among others.
GSK-269962A is a Rho kinase (ROCK) inhibitor with both ROCK1 and ROCK2 affinity.[A253012]
Deskripsi belum tersedia.
Deskripsi belum tersedia.
GSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis).
Deskripsi belum tersedia.
GSK-3117391 is under investigation in clinical trial NCT02965599 (Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis).
Gsk356278 has been used in trials studying the treatment and basic science of Anxiety Disorders, Huntington Disease, Depressive Disorder, Huntingtons Disease, and Depressive Disorder, Major, among others.
GSK-364735 (Naphthyridinone) has been used in trials studying the treatment of HIV-1 Infection and Infection, Human Immunodeficiency Virus.
GSK376501 has been used in trials studying the treatment and diagnostic of Type 2 Diabetes Mellitus.
Gsk424887 has been used in trials studying the basic science and treatment of Depressive Disorder and Anxiety Disorder.
GSK690693 has been used in trials studying the treatment of Tumor, CANCER, and Lymphoma.
GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline (GSK). GSK-923295 demonstrated a broad spect…
GSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effe…
GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
GSK2245035 is under investigation in clinical trial NCT02833974 (Effect of the GSK2245035 on the Allergen-induced Asthmatic Response).
GSK2256098 is under investigation in clinical trial NCT02523014 (Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas).
GSK232802 is under investigation in clinical trial NCT00604825 (Treatment of Hot Flashes/flushes in Postmenopausal Women (WARM Study)).
GSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough).
GsMtx-4 is a peptide found in tarantula venom that inhibits mechanosensitive ion channel (MSC) activity.
Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and MAD) Phase I trials. It is expected to block fat absorpti…
GT-AS recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP.
GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of Interleukin 15 (IL-15).
GTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.
GTI-2040 is under investigation in clinical trial NCT00084643 (GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors).
GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate canc…
GTP-506 is a gene therapy formed by two vectors, a nuclease vector targeting gene editing in the well-characterized PCSK9 gene locus and a therapeutic donor vector that inserts the OTC gene to provide the desired genetic correction.
GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athenagen licensed the exc…
GTX-102 is an antisense oligonucleotide designed to target and inhibit the expression of UBE3A-AS. It is being investigated for the treatment of Angelman Syndrome.[L46772]